AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01198366 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AERAS-402 3.0 x 10^10 vp
Study NCT01198366 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AERAS-402 1.0 x 10^11 vp
Study NCT01198366 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01557335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plavix® and PA32540
Description: one Plavix® 300 mg loading dose in the PM of Day 1 one Plavix® 75 mg maintenance dose in the PM of Days 2-7 PA32540(delayed release aspirin 325 mg plus immediate release omeprazole 40 mg)
Study NCT01557335 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EC aspirin (Bayer®) ,EC omeprazole (Prilosec®) , Clopidogrel (Plavix®)
Description: One EC aspirin (Bayer®) 81 mg tablet plus one EC omeprazole (Prilosec®) 40 mg capsule plus one Clopidogrel (Plavix®) tablet of 300 mg (loading dose) all One EC aspirin (Bayer®) 81 mg tablet plus one EC omeprazole (Prilosec®) 40 mg capsule plus one Clopidogrel (Plavix®) tablet of 75 mg (maintenance dose) all taken concomitantly in the AM of Days 2-7
Study NCT02538653 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sandwich biscuit high in SDS
Description: Consumption of the high SDS product (50g) alone with a glass of water
Study NCT02538653 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Co-extruded cereal low in SDS
Description: Consumption of the low SDS product (48.3 g) alone with a glass of water
Study NCT03312322 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-frequency transcutaneous electrical nerve stimulation
Description: 4 self adhesive surface electrodes are positioned by pair at the L3-L4 level, laterally.~Stimulation is setted at rest, 10min before constant workload testing. During this period, intensity is increased every 3minutes to the maximum tolerated by the patient (pain threshold). Thereafter, intensity is not increased anymore during the test.~It is explained to the patient that he might or no experience the electrical stimulation sensation.~Current characteristics : 100Hertz, 100ms, bidirectional. Constant workload testing : 60-70rpm ; 75% Wpic ; up to exhaustion or rpm \< 60 during more than 10s.
Study NCT01231126 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Misoprostol
Description: Procedures were taken for induced labor delivery with misoprostol 25mcg, by vaginal rout. The pills were administered each 6 hours in a maximum number of six.
Study NCT04492787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Changkang Granule
Description: Take Changkang granule before meals twice a day , one bag for each time
Study NCT04492787 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Changkang Placebo Granule
Description: Take Changkang Placebo granule before meals twice a day , one bag for each time
Study NCT03948451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]AZD5718 Oral Suspension
Description: 200 mg dose of \[14C\]AZD5718 Oral Suspension
Study NCT02450500 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle counselling
Description: This will consist of a web-based lifestyle app and personalised behaviour modification advice by a registered dietitian delivered via messaging. Participants will be issued with a pedometer and instructed to wear this daily. Participants will access web-based material on prediabetes through the lifestyle app. Contact between the dietitian and participants will consist of weekly messaging to facilitate changes in diet and activity behaviour through motivational and cognitive behavioural strategies. Changes in diet and activity levels will be recorded as personalised goals which will be monitored and reviewed by both the participants and dietitian. In addition participants will be encouraged to complete a food diary to self-monitor their progress against dietary recommendations.
Study NCT03312322 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-frequency transcutaneous electrical nerve stimulation
Description: 4 self adhesive surface electrodes are positioned by pair at the L3-L4 level, laterally.~Stimulation is setted at rest, 10min before constant workload testing. During this period, intensity is increased every 3minutes to the maximum tolerated by the patient (pain threshold). Thereafter, intensity is not increased anymore during the test.~It is explained to the patient that he might or no experience the electrical stimulation sensation.~Current characteristics : 4Hertz, 100ms, bidirectional. Constant workload testing : 60-70rpm ; 75% Wpic ; up to exhaustion or rpm \< 60 during more than 10s.
Study NCT03312322 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham transcutaneous electrical nerve stimulation
Description: The procedure is the same as high-frequency transcutaneous electrical stimulation but intensity is progressively setted back to 1mA (over a 45sec period) after every increment so that constant workload testing is performed with 1mA.
Study NCT00650104 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropinirole XL (formerly CR)
Description: Active Ropinirole CR tablets of 2.0mg, 4.0mg, 8.0mg where subjects can tritrate to an stable optimum dose level of either 2.0mg, 4.0mg, 6.0mg, 8.0mg, 12mg, 16mg, 20mg, or 24mg per day.
Study NCT01318967 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide
Description: Renal blood flow is measured after the administration of 20 mg of furosemide during MRI scan only.
Study NCT01318967 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02277574 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMP-110
Description: 2, 5, or 10 mg/kg
Study NCT04490304 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: durability of posterior soft tissue repair
Description: how durable is the posterior soft tissue repair after total hip arthroplasty in primary osteoarthiritis patients?
Study NCT02652091 — intervention group
Intervention type: DRUG
Intervention: Interferon beta-1b (Betaseron, BAY86-5046)
Description: Applied via the BETACONNECT device. Dose as prescribed by physician.
Study NCT02652091 — intervention group
Intervention type: DEVICE
Intervention: BETACONNECT device
Description: Used to apply Betaseron.
Study NCT01178034 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Calculate warfarin dose using demographic/genetic algorithm
Description: Age, body weight and genetic to calculate warfarin dosage
Study NCT02277574 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT00220584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: donepezil
Description: donepezil 5 mg daily for 3 weeks (days 1-21); 10 mg daily for 3 weeks (days 22-42)
Study NCT03889964 — intervention group
Intervention type: OTHER
Intervention: Measurement of lung function, electrocardiography, echocardiography and cardiopulmonary exercise testing
Description: Measurement of lung function, electrocardiography, echocardiography and cardiopulmonary exercise testing
Study NCT04165460 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Description: Delivering systematic information about cancer, oncological treatment and efficient coping strategies.
Study NCT04165460 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: Delivering systematic information about cancer, oncological treatment and efficient coping strategies.
Study NCT04165460 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Relaxation
Description: Teaching the patient in diaphragmatic breathing retraining and passive relaxation with guided imagination.
Study NCT04165460 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation
Description: Teaching the patient in diaphragmatic breathing retraining and passive relaxation with guided imagination.
Study NCT04165460 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Restructuring
Description: Teaching the patient to identify dysfunctional cognitions about cancer and oncological treatment that trigger maladaptive emotions and behavior. Then, focus in generating alternative thoughts through contrast with empirical reality based on the Beck Model.
Study NCT04165460 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Solving Problems
Description: To generate alternative solutions to practical problems based on the model described by Nezu.
Study NCT04373148 — intervention group
Intervention type: OTHER
Intervention: There is no intervention
Description: There is no intervention
Study NCT00797264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine-Morphine
Description: Ketamine bolus preoperative and syringe pump peroperative, and morphine postoperative (PCA)
Study NCT00797264 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Bolus preoperative of NaCl and syringe pump peroperative of NaCl, and morphine postoperative (PCA)
Study NCT01574716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MORAb-004
Description: IV, Days 1 and 8 of every cycle until disease progression
Study NCT01574716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: IV, Days 1 and 8 of each cycle until disease progression
Study NCT01574716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: IV, Day 8 of every cycle until disease progression
Study NCT03135288 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cell-phone
Description: a reminder of their postpartum family planning visit 5 weeks after the delivery (one week before the scheduled visit) and a phone call 48 hours before the scheduled visit. They will also receive two follow-up phone calls to answer any questions and to remind them with the follow-up visits after insertion. Woman will be given a referral card to the outpatients' family planning clinic denoting her study group and serial number and with a specific date for postpartum family planning visits.
Study NCT01574716 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: IV, Days 1 and 8 of each cycle until disease progression
Study NCT01574716 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: IV, Day 8 of every cycle until disease progression
Study NCT01574716 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT00797264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Postoperative PCA of Ketamine and morphine
Description: Bolus preoperative of NaCl and syringe pump peroperative of Ketamine, and morphine postoperative (PCA)
Study NCT03299244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etelcalcetide
Description: Administered intravenously three times per week.
Study NCT03299244 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cinacalcet
Description: Cinacalcet administered orally once a day.
Study NCT01574287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FACBC
Description: Drug is give intravenously over 2 minutes at time of scan
Study NCT01455922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITCA 650
Description: ITCA 650 is exenatide in DUROS
Study NCT01455922 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glimepiride
Description: glimepiride will be up-titrated to 8 mg/day over first 13 weeks
Study NCT01927523 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BAM
Description: BAM (Becoming a Man), a cognitive-behavioral group therapy intervention.
Study NCT01927523 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Match
Description: An intensive math tutoring program.
Study NCT03266744 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Computerised Tomography
Study NCT03266744 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Whole Body Magnetic Resonance Imaging
Study NCT00778726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benazepril HCl/ Hydrochlorothiazide 20 mg/ 25 mg Tablets
Study NCT00778726 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benazepril HCl/ Hydrochlorothiazide 20 mg/ 25 mg Tablets
Study NCT01590212 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mellow Bumps
Description: Mellow Bumps is a six week group-based antenatal programme designed to support families with additional health and social care needs. It is intended to decrease maternal antenatal stress levels, increase expectant mothers' understanding of neonates' capacity for social interaction and emphasise the importance of early interaction in enhancing brain development and attachment. It is delivered non-didactically to maximise participant engagement and rapport. Each week there is one activity focused on the woman and another on a baby-related topic. The programme is designed to be offered between twenty to thirty weeks' gestation, to capture the period when the risk of miscarriage is low and fetal movement felt, but before major preoccupation with the delivery.
Study NCT03266744 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Bone scan
Study NCT01590212 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chill-out in Pregnancy
Description: Chill Out in Pregnancy (ChIP) is a relaxation programme that includes all the mother centred components of Mellow Bumps but none of the baby / mother-baby relationship components. It also runs for six weeks at two hours per week and is intended to decrease stress levels.
Study NCT01541111 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Magnesiun
Description: 75mg pills; each 12h; 12wk
Study NCT00762268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAMe
Description: SAMe tablets will be administered intermittently and in steadily increasing dosages. Subjects will receive oral SAMe for only 3 days per week, followed by a 4 day rest-period, before the next dosage increase. SAMe dosage will be progressively increased each week to a maximum of 1600 mg per day over a 4-week period.
Study NCT00762268 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03858296 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered emotional awareness training
Description: Emotional awareness training is delivered via an internet platform during 4 weeks and includes therapist contact several times per week via the platform.
Study NCT03858296 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered Cognitive reappraisal training
Description: Cognitive reappraisal training is delivered via an internet platform during 4 weeks and includes therapist contact several times per week via the platform.
Study NCT04476446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: Participants will receive esketamine at doses of either 56 mg or 84 mg intranasally once or twice a week based on the investigator's clinical judgment.
Study NCT03335150 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CogSMART-PD
Description: Cognitive Rehabilitation for persons with PD-MCI
Study NCT03335150 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Care
Description: Support Group for persons with PD-MCI
Study NCT03838211 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Description: Anodal transcranial direct current stimulation (tDCS), 9 sessions with 20 minutes stimulation each (current intensity of 1mA)
Study NCT03838211 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Intensive cognitive training
Description: Intensive cognitive training of a letter memory updating task and a 3-stage Markov decision making task, 9 sessions
Study NCT03838211 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive cognitive training
Description: Intensive cognitive training of a letter memory updating task and a 3-stage Markov decision making task, 9 sessions
Study NCT06094244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Doses of atorvastatin of up to 20 mg/d.
Study NCT06094244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Doses of rosuvastatin of up to 10 mg/d.
Study NCT00721500 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: narafilcon A
Description: contact lens
Study NCT00681213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus/Sirolimus
Study NCT00681213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus/MMF
Study NCT02023567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSRIs
Description: fluoxertine hydrochloride 20-60mg/day, paroxetine hydrochloride 20-60mg/day, sertraline hydrochloride 50-200mg/day, citalopram 20-60mg/day, escitalopram 10-20mg/day, fluvoxamine 50-300mg/day
Study NCT03858296 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered awareness and reappraisal training
Description: Emotional awareness and cognitive reappraisal training is delivered via an internet platform during 4 weeks and includes therapist contact several times per week via the platform.
Study NCT01822223 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dental implant-abutments
Description: At week-8, abutments will be removed and replaced with new Laser-Lok® abutments. An inter-arm randomization will assign subjects to one of two sub-groups per treatment arm. Sub-groups 1-a \& 2-a: will receive a new Laser-Lok® abutment and a soft-tissue biopsy at week-8; a force-probe clinical attachment assessment of the same site will be delayed until week-16.~Sub-groups 1-b \& 2-b: will receive a new Laser-Lok® abutment and a force-probe clinical attachment assessment at week-8; a biopsy harvested from the same study site will be delayed until week-16.~The implants will be restored following standard technique and a final visit will occur 6 months following permanent restoration.
Study NCT01822223 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dental implant-abutments
Description: At week-8, abutments will be removed and replaced with new Laser-Lok® abutments. An inter-arm randomization will assign subjects to one of two sub-groups per treatment arm. Sub-groups 1-a \& 2-a: will receive a new Laser-Lok® abutment and a soft-tissue biopsy at week-8; a force-probe clinical attachment assessment of the same site will be delayed until week-16.~Sub-groups 1-b \& 2-b: will receive a new Laser-Lok® abutment and a force-probe clinical attachment assessment at week-8; a biopsy harvested from the same study site will be delayed until week-16.~The implants will be restored following standard technique and a final visit will occur 6 months following permanent restoration.
Study NCT01006213 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational intervention
Description: Two groups will be established in geographically separate areas, one of which will receive the group motivational intervention (intervention group) and the other will receive standard follow-up (control group)
Study NCT06094244 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No drugs
Description: No drugs
Study NCT00809926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan/aliskiren
Description: Valsartan/aliskiren (160/150mg) for 2 weeks followed by forced titration to valsartan/aliskiren (320/300mg) for the remaining 6 weeks
Study NCT00809926 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Description: Valsartan (160mg) for 2 weeks followed by forced titration to Valsartan (320mg) for the remaining 6 weeks
Study NCT01503346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DaHuang GanTsao Tang
Description: Intervention group~1. 2 grams of DaHuang abstract powder and 0.5 grams GanTsao abstract powder are mixed and separated into four packages;~2. each package was given to each patient four times a day (three time after meal and one time before sleep);~3. each patient received the usual medication of the hospice ward at the same time;~4. record the patients' score of pre-test, mid-test and after-test of QIPCTP at the 1st day, the 3rd day and the 6th day;~5. record the patients' score of EORTC QLQ-C30 V3.0 and ECOG (Eastern Cooperative Oncology Group Performance Status) at the 1st day and the 6th day.
Study NCT03437291 — intervention group
Intervention type: PROCEDURE
Intervention: Cesarean section
Description: Lower segment CS with evaluation of Placental site, spontaneous separation, placental invasion into the bladder and other surrounding organs, Uterotonic administration, Bladder , ureteric or bowel injury, blood loss and blood transfusion
Study NCT03437291 — intervention group
Intervention type: DEVICE
Intervention: Transabdominal ultrasound
Description: loss of clear zone, Abnormal placental lacunae, Bladder wall interruption, Myometrial thinning, Placental bulge, Focal exophytic mass
Study NCT03437291 — intervention group
Intervention type: DEVICE
Intervention: Transvaginal ultrasound
Description: loss of clear zone, Abnormal placental lacunae, Bladder wall interruption, Myometrial thinning, Placental bulge, Focal exophytic mass
Study NCT01001572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan/amlodipine 160/5 mg
Description: Valsartan/amlodipine 160/5mg film coated tablets taken orally once daily.
Study NCT01001572 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Valsartan 160 mg
Description: Valsartan 160 mg capsule taken orally once daily.
Study NCT01001572 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan 160 mg
Description: Valsartan 160 mg capsule taken orally once daily.
Study NCT01001572 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 1 capsule or tablet taken orally once daily